Fournier's gangrene and sodium-glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials

Diabetes, Obesity and Metabolism

Volumn 22, Issue 2, 2020, Pages 272-275

  Silverii, Giovanni Antonio ^a   Dicembrini, Ilaria ^a   Monami, Matteo ^b   Mannucci, Edoardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

antidiabetic drug; Fournier's gangrene; meta analysis; sodium glucose co transporter 2 inhibitor

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN;

ABSCESS; ARTICLE; CELLULITIS; DRUG SAFETY; ERYSIPELAS; FOURNIER GANGRENE; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT DURATION; ADVERSE EVENT; AGED; DIABETIC COMPLICATION; FEMALE; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SOFT TISSUE INFECTION;

AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOURNIER GANGRENE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SOFT TISSUE INFECTIONS;

EID: 85075246523     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13900     Document Type: Article

References (15)

1. Kaufmann JA, Ramponi D. Recognition of risk factors and prognostic indicators in Fournier's gangrene. Crit Care Nurs Q. 2015;38:143-153.
2. Sorensen MD, Krieger JN. Fournier's gangrene: epidemiology and outcomes in the general US population. Urol Int. 2016;97:249-259.
3. The U.S. Food and Drug Administration (2018). Drug safety communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Safety Announcement (August 29, 2018).
4. Onder CE, Gursoy K, Kuskonmaz SM, Kocer U, Culha C. Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes. J Diabetes. 2019;11:348-350.
5. Kumar S, Costello AJ, Colman PG. Fournier's gangrene in a man on empagliflozin for treatment of type 2 diabetes. Diabet Med. 2017;34:1646-1648.
6. Cecilia-Chi W, Lim-Tio S. Fournier's syndrome: a life threatening complication of SGLT2 inhibition in poorly controlled diabetes mellitus. Joint Annual Scientific Meeting of the Australian Diabetes Educators Association (ADEA) and Australian Diabetes; Aug 24-26 2016, Gold Coast, Queensland. Available at: http://ads-adea-2016.m.asnevents.com.au/.
7. Omer T, Sree Dharan S, Adler A. Sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin and Fournier's gangrene: a life threatening severe adverse outcome. Case report. Diabet Med. 2018;35:100.
8. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7:2824.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med. 2009;151:264-269.
10. HCUP US (2018). Trend weights for HCUP NIS data. https://www.hcupus.ahrq.gov/db/nation/nis/trendwghts.jsp. Accessed December 25, 2018.
11. Çakmak A, Genç V, Akyol C, Ayhan Kayaoğlu H, Hazinedaroğlu SM. Fournier's gangrene: is it scrotal gangrene? Adv Ther. 2008;25:1065-1074.
12. Wiviott SD, Raz I, Bonaca MP, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357.
13. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374:1094.
14. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
15. Kosiborod M, Cavender MA, Fu AZ, et al; CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249-259.